Could an immune checkpoint drug slow Alzheimer's? early trial begins
Disease control
Completed
This first-in-human study tested a new drug called IBC-Ab002 in 40 people with early Alzheimer's disease. The drug is an antibody that targets PD-L1, a protein involved in immune regulation. The main goal was to check safety and how the drug moves through the body, not yet to pro…
Phase: PHASE1 • Sponsor: Immunobrain Checkpoint • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC